Scarica l'app Stockscreener
2.22
5.53%
-0.13
Dopo l'orario di chiusura:
2.22
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Atossa Therapeutics Inc Borsa (ATOS) Ultime notizie
Atossa Therapeutics brings medical innovation to Hudson Institute strategic discussions - Traders Union
Atossa Therapeutics (ATOS) Q1 2026 Earnings: Narrowing Losses with Positive EPS SurpriseRevenue Warning Signal - newsline.com
Atossa Therapeutics closes $4.5M registered direct offering By Investing.com - Investing.com Australia
Atossa Therapeutics closes $4.5M registered direct offering - Investing.com UK
Cancer-drug developer Atossa raises $4.5M, eyes $12M more - Stock Titan
Atossa Therapeutics Announces Up To $16.5 Million Registered Direct Offering - Pulse 2.0
Atossa Therapeutics examines biosecurity and scientific innovation after COVID 19 lessons - Traders Union
Atossa Therapeutics (NASDAQ: ATOS) sells 1.36M shares with warrants in $4.5M deal - Stock Titan
Atossa Therapeutics prices up to $16.5M direct offering - MSN
Market Movers | Winners: XXII, PPCB, CCHH | Losers: BCPC, ATOS, BATL - Trefis
Atossa Therapeutics, Inc. (ATOS) Latest Stock News & Headlines - Yahoo Finance
Top Midday Decliners - Moomoo
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings - Benzinga
Dow Jumps Over 250 Points; US Initial Jobless Claims RiseAtossa Therapeutics (NASDAQ:ATOS), Big Tree C - Benzinga
Atossa Therapeutics Launches $16.5 Million Registered Direct Offering - marketscreener.com
Atossa Therapeutics stock tumbles on $4.5M stock offering - Investing.com UK
Atossa Therapeutics Announces Registered Direct Offering and Warrants - TipRanks
Atossa Therapeutics stock tumbles on $4.5M stock offering By Investing.com - Investing.com UK
Atossa Therapeutics raises $4.5M in registered direct offering - Investing.com
Atossa Therapeutics raises $4.5M in registered direct offering By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Atossa Therapeutics Prices Registered Direct Offering at $3.30, Netting About $4.1 Million - TradingView
Atossa Therapeutics (ATOS) prices $3.30 registered direct stock and warrant sale - Stock Titan
Biotech Atossa targets up to $16.5M to fund clinical work - Stock Titan
ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug - Stocktwits
Atossa Therapeutics highlights Endoxifen progress as potential Breast Cancer treatment - Proactive financial news
Atossa Therapeutics (ATOS) Climbs 1.79% as Shares Approach Key Resistance at $4.78Wedge Breakout - newsline.com
Lowering mammographic breast density could cut future cancer risk, ATOSSA THERAPEUTICS, INC. asserts - Traders Union
CEO Chat with Steven Quay, MD, PhD, Chairman, President, & CEO of Atossa Therapeutics - Yahoo Finance
Atossa Therapeutics (ATOS) Edges Higher on Modest Gains, Holds Above Key SupportReversal Trade - The Legal Advocate
ATOS News | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Cash from investing activities of Atossa Therapeutics, Inc. – DUS:YAG - TradingView
Atossa Therapeutics (ATOS) Highlights Promising Data for (Z)-End - GuruFocus
Atossa presents preclinical data on breast cancer drug at ASCO - Investing.com UK
Atossa Presents New Data Highlighting (Z)-Endoxifen's Potential in Breast Cancer - Intellectia AI
Atossa Therapeutics Announces ASCO 2026 Abstracts Highlighting (Z)-Endoxifen Activity Across ESR1 Mutations and Ongoing EVANGELINE Phase 2 Trial - PR Newswire
(Z)-Endoxifen hits ESR1 breast cancer mutations in new trial - Stock Titan
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
ATOS Stock Price, Quote & Chart | ATOSSA THERAPEUTICS INC (NASDAQ:ATOS) - ChartMill
Atossa Therapeutics (ATOS) Holds Steady Near Support Amid Modest DeclineScalping Stock Signals - newsline.com
Atossa Therapeutics Announces Acceptance of Manuscript Highlighting Utrophin-Modulation Potential of (Z)-Endoxifen in Duchenne Muscular Dystrophy - BioSpace
Atossa Therapeutics advances research on Z-endoxifen for Duchenne muscular dystrophy - Traders Union
Atossa's New Research Findings on DMD - Intellectia AI
Atossa Therapeutics (ATOS) price target decreased by 47.43% to 23.46 - MSN
ATOS Should I Buy - Intellectia AI
Atossa Therapeutics (ATOS) director granted 10,000 RSUs vesting after 2026 - Stock Titan
ATOS (ATOS) director Stephen Galli receives 10,000 RSU equity grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000 RSUs in stock award - Stock Titan
Atossa (NASDAQ: ATOS) director awarded 10,000 RSUs in stock grant - Stock Titan
Atossa Therapeutics (ATOS) director granted 10,000-share RSU award - Stock Titan
Atossa Therapeutics (NASDAQ: ATOS) director receives 10,000 RSUs award - Stock Titan
Atossa Therapeutics brings experts together to examine endocrine therapy backbone potential - Traders Union
Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer - BioSpace
Atossa Therapeutics, Inc. (ATOS) latest stock news and headlines - Yahoo Finance Singapore
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):